• Sitemap
  • Contact Us

pISSN 2950-9114 eISSN 2950-9122
Article View

Original Article

J Lab Med Qual Assur 2014; 36(1): 30-38

Published online March 31, 2014


Copyright © Korean Association of External Quality Assessment Service.

Performance Evaluation of the SelexOn Analyser for Seven Biomarkers

Hyun-Young Kim, Soo-Youn Lee, and Hyung-Doo Park

Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to:Hyung-Doo Park
Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea
Tel: +82-2-3410-0290
Fax: +82-2-3410-2719
E-mail: nayadoo@hanmail.net

Received: October 16, 2013; Revised: January 31, 2014; Accepted: February 19, 2014

Background: SelexOn (Infopia, Korea) is a novel immunoassay instrument that measures the concentration of α-fetoprotein (AFP), creatine kinase isoenzyme (CK-MB), D-dimer, high-sensitivity C-reactive protein (hs-CRP), myoglobin, prostate-specific antigen (PSA), and thyroid-stimulating hormone (TSH) in whole blood. We evaluated the analytical performance of SelexOn.
Methods: The analytical performance of SelexOn was evaluated for precision and linearity, and compared with the ADVIA Centaur XP Immunoassay System (Siemens, Germany) and the STA-R coagulation analyser (Diagnostica Stago, France).
Results: Within-run CV ranged from 2.9% to 8.9% for all biomarkers. Between-run precision ranged from 1.6% to 11.3% for all biomarkers, except at low levels of D-dimer (16.1%). Observed linearity ranges were AFP, 8.7 to 47.0 ng/mL; CK-MB, 4.7 to 38.7 ng/mL; D-dimer, 393.2 to 2,760.3 ng/mL; hs-CRP, 2.1 to 9.0 mg/L; myoglobin, 67.2 to 441.5 ng/mL; PSA, 2.6 to 23.7 ng/mL; and TSH, 3.3 to 38.9 mIU/L. Upon comparing SelexOn with the Centaur XP and STA-R systems, values of AFP, CK-MB, hs-CRP, and PSA showed good correlation, with correlation coefficients greater than 0.975. The correlation coefficients of TSH, myoglobin, and D-dimer were 0.9723, 0.9649, and 0.8379, respectively. The concordance was excellent for hs-CRP (kappa [κ]=0.958), PSA (κ=0.854), and TSH (κ=0.810); good for AFP (κ=0.655), CK-MB (κ=0.759), and myoglobin (κ=0.783); and moderate for D-dimer (κ=0.561).
Conclusions: SelexOn demonstrated acceptable precision, linearity, and correlation with the Centaur XP and the STA-R for seven biomarkers. Because of its speed and performance, SelexOn may facilitate the rapid screening of patients for cardiovascular disease, thyroid disease, prostate cancer, and hepatocellular carcinoma.
(J Lab Med Qual Assur 2014;36:30-38)

Keywords: Immunoassay, Cardiovascular diseases, Performance, Tumour markers

  1. Gregory AH, Katherine IS. Point-of-care and physician office laboratories. In: Henry JB, McPherson RA, Pincus MR, editor. Henry’s clinical diagnosis and management by laboratory methods. 22nd ed. Philadelphia (PA):Elsevier/Saunders, 2011: 87-93.
  2. Nichols JH. Point of care testing. Clin Lab Med 2007;27:893-908, viii.
    Pubmed CrossRef
  3. Von Lode P. Point-of-care immunotesting: approaching the analytical performance of central laboratory methods. Clin Biochem 2005;38:591-606.
    Pubmed CrossRef
  4. Fraser CG. Optimal analytical performance for point of care testing. Clin Chim Acta 2001;307:37-43.
  5. Clinical and Laboratory Standards Institute. Evaluation of precision performance of quantitative measurement methods: approved guideline-second edition. Wayne (PA): Clinical and Laboratory Standards Institute, 2004.
  6. Clinical and Laboratory Standards Institute. Evaluation of the linearity of quantitative measurement procedure:a statistical approach: approved guideline. Wayne (PA):Clinical and Laboratory Standards Institute, 2003.
  7. Clinical and Laboratory Standards Institute. Method comparison and bias estimation using patient samples:approved guidelines. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute, 2010.
  8. Altman DG. Practical statistics for medical research. Boca Raton (FL): Chapman and Hall, 1999.
  9. Ricos C, Alvarez V, Cava F, Garcia-Lario JV, Hernandez A, Jimenez CV, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491-500.
    Pubmed CrossRef
  10. Yang J, Chae H, Lee J, Kim Y, Kim SY, Lee HK, et al. Evaluation of HUBI-QUANPRO point-of-care testing for cardiac markers. J Lab Med Qual Assur 2011;33:75-82.
  11. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010;56:e1-48.
    Pubmed CrossRef
  12. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008;54:e11-79.
    Pubmed CrossRef
  13. Lewandrowski K, Chen A, Januzzi J. Cardiac markers for myocardial infarction: a brief review. Am J Clin Pathol 2002;118 Suppl:S93-9.
  14. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50:327-32.
    Pubmed CrossRef
  15. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444-50.
  16. Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement:implications for cardiovascular disease risk assessment. Clin Chem 2003;49:1258-71.
  17. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
    Pubmed CrossRef
  18. Roberts WL, Sedrick R, Moulton L, Spencer A, Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem 2000;46:461-8.
  19. Di Nisio M, Squizzato A, Rutjes AW, Buller HR, Zwinderman AH, Bossuyt PM. Diagnostic accuracy of D-dimer test for exclusion of venous thromboembolism:a systematic review. J Thromb Haemost 2007;5:296-304.
    Pubmed CrossRef
  20. Sidelmann JJ, Gram J, Larsen A, Overgaard K, Jespersen J. Analytical and clinical validation of a new point-of-care testing system for determination of D-Dimer in human blood. Thromb Res 2010;126:524-30.
    Pubmed CrossRef
  21. Elf JL, Strandberg K, Svensson PJ. Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis. Thromb Res 2009;124:701-5.
    Pubmed CrossRef
  22. Reix N, Massart C, d’Herbomez M, Gasser F, Heurtault B, Agin A. Thyroid-stimulating hormone and free thyroxine on the ADVIA Centaur immunoassay system:a multicenter assessment of analytical performance. Clin Biochem 2013;46:1305-8.
    Pubmed CrossRef

Supplementary File

Share this article on :

Stats or metrics